← ANALYST RATINGS · TIPRANKS
Bright Minds Biosciences (DRUG): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $172, the highest $220, the lowest $145. The average is +234.6% from the last price of $51.30.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $150 | Buy | +192.4% | Initiated | 15.10.26on TipRanks 06:20 | +6.6%next day −4.3% | ↗ |
| AI xAi Health Care CAxAI Grok-3 | TipRanks - xAI | $54.00 → $53.00−1.9% | Hold | +3.3% | Reiterated | 08.10.26on TipRanks 10:05 | — | |
| AI DeepSeek Health Care CADeepSeek V3.2-Speciale | TipRanks - DeepSeek | $50.00 → $49.00−2.0% | Sell | −4.5% | Reiterated | 08.10.26on TipRanks 10:05 | — | |
| AI OpenAI Health Care CAOpenAI 5.2 | TipRanks - OpenAI | $52.00 → $51.00−1.9% | Hold | −0.6% | Reiterated | 08.10.26on TipRanks 10:05 | — | |
| AI Anthropic Health Care CAAnthropic Opus-4.5 | TipRanks - Anthropic | $52.00 → $50.00−3.8% | Hold | −2.5% | Reiterated | 08.10.26on TipRanks 10:05 | — | |
| AI Google Health Care CAGemini 3-pro | TipRanks - Google | $52.00 → $50.00−3.8% | Hold | −2.5% | Reiterated | 08.10.26on TipRanks 10:05 | — | |
| AI PerPlexity Health Care CAPerPlexity SonarPro | TipRanks - PerPlexity | $52.00 → $50.00−3.8% | Hold | −2.5% | Reiterated | 08.10.26on TipRanks 10:05 | — | |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $146 | Buy | +184.6% | Initiated | 03.10.26on TipRanks Oct 5 05:10 | −2.4%next day −3.6% · 5 days +8.1% | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $220 | Buy | +328.8% | Reiterated | 01.10.26on TipRanks 07:08 | −1.4%next day +2.3% · 5 days +4.4% | ↗ |
| Patrick Trucchio★★★★★★★★★★#79 · hits 58% · avg +37.9% | H.C. Wainwright | $145 | Buy | +182.7% | Reiterated | 21.09.26on TipRanks Sep 22 05:45 | −4.0%next day +2.1% · 5 days −12.1% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 16.08.26on TipRanks Aug 17 05:36 | +4.4%next day +6.4% · 5 days −1.9% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $145 | Buy | +182.7% | Initiated | 12.04.26on TipRanks 19:25 | +1.0%next day +3.4% · 5 days +3.3% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $147 | Buy | +186.5% | Reiterated | 30.03.26on TipRanks 05:55 | −2.0%next day +3.7% · 5 days +8.0% | ↗ |
| Charles Moore★★★★★★★★★★#5625 · hits 71% · avg +14.1% | Robert W. Baird | $142 → $126−11.3% | Buy | +145.6% | Reiterated | 13.02.26on TipRanks 09:25 | −3.4%next day +7.6% · 5 days +10.9% | ↗ |
| Unknown Analyst | Chardan Capital | $80.00 | Buy | +55.9% | Initiated | 31.12.25on TipRanks 18:45 | +6.8%next day −4.8% · 5 days +2.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Bright Minds Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $170 at a price of $49.82 (+241.9%); now: $165 at $51.30 (+222.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 4 | 4 | 3 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.12.26 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.15 (from $-1.78 to $-0.44). Last quarter: $-0.17.
Best top-analyst consensus in the sector · Healthcare
About Bright Minds Biosciences
- CEO: Ian McDonald
- Employees: 26
- 19 Vestry Street, New York, NY, 10013, US
- www.brightmindsbio.com
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Data from the stock’s TipRanks forecast page, read 121 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗